Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02953587 · ClinicalTrials.gov registry record · Phase 1
Effect of Ghrelin on Glucose Metabolism After Bariatric Surgery
A Phase 1 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT02953587 is a Phase 1 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 70 participants.
The verdict
NCT02953587, a Phase 1 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the altered nutrient exposure to the GI tract after bariatric surgery reveals a negative incretin effect of ghrelin.
Interventions
- DRUG Saline
- PROCEDURE Oral Glucose Tolerance Test (OGTT)
- DRUG Human Ghrelin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2016-09 |
| Est. Completion | 2023-01-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02953587
The ClinicalTrials.gov registry entry for NCT02953587 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Saline is the first listed.
NCT02953587 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02953587 about?
NCT02953587 is a clinical study titled "Effect of Ghrelin on Glucose Metabolism After Bariatric Surgery". The purpose of this study is to determine if the altered nutrient exposure to the GI tract after bariatric surgery reveals a negative incretin effect of ghrelin.
What is the current status of trial NCT02953587?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2016-09. Estimated completion is 2023-01-30.
What interventions are being tested in trial NCT02953587?
The interventions under investigation include: Saline (DRUG), Oral Glucose Tolerance Test (OGTT) (PROCEDURE), Human Ghrelin (DRUG).
Who is sponsoring clinical trial NCT02953587?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.